Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02955394 · ClinicalTrials.gov registry record · Phase 2
Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer
A Phase 2 study of Breast Cancer, sponsored by University of Colorado, Denver.
- Active
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
- 3
- Study locations
NCT02955394 is a Phase 2 study of Breast Cancer that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 61 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT02955394, a Phase 2 study of Breast Cancer, is active but no longer recruiting, sponsored by University of Colorado, Denver.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a randomized two arm phase II study to further evaluate the efficacy of fulvestrant plus enza compared to single agent fulvestrant in postmenopausal women with locally advanced AR+/ER+/Her2- BC who will have local surgery after \~4 months on treatment.
Conditions Studied
Interventions
- DRUG Fulvestrant
- DRUG Enzalutamide
Study Locations (3)
Colorado
- University of Colorado - Aurora
New York
- Memorial Sloan Kettering Cancer Center - New York
Tennessee
- West Cancer Center - Germantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2017-09-21 |
| Est. Completion | 2027-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02955394
The ClinicalTrials.gov registry entry for NCT02955394 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Fulvestrant is the first listed.
NCT02955394 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Colorado, New York, Tennessee.
Frequently Asked Questions
What is clinical trial NCT02955394 about?
NCT02955394 is a clinical study titled "Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer". This is a randomized two arm phase II study to further evaluate the efficacy of fulvestrant plus enza compared to single agent fulvestrant in postmenopausal women with locally advanced AR+/ER+/Her2- BC who will have local surgery after \~4 months on treatment.
What is the current status of trial NCT02955394?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2017-09-21. Estimated completion is 2027-02.
What conditions does trial NCT02955394 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT02955394?
The interventions under investigation include: Fulvestrant (DRUG), Enzalutamide (DRUG).
Who is sponsoring clinical trial NCT02955394?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02955394 being conducted?
This trial has 3 study locations across Colorado, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.